Target 1: Replication protein A (RPA) (NIH STTR funded Study to NERx)
- NERx-20-04, Lead Candidate
- Robust single agent activity.
- Synergistic activity with clinically validated DNA repair targeted agents.
- In vivo tolerability and efficacy.
Target 2: Xeroderma Pigmentosum group A protein (XPA) (NIH Funded STTR to NERx, NIH R01 funded study IU)
- NERx-X80 class of compounds
- Validated hit
- Highly potent and specific inhibitor of XPA
- Excellent cellular uptake and metabolism